OPKO (OPK) BLA Review for Growth Hormone Deficiency Drug Delayed

Posted byZacks Equity Research Leave a comment on OPKO (OPK) BLA Review for Growth Hormone Deficiency Drug Delayed

The FDA extends the PDUFA action date for OPKO (OPK)/Pfizer’s BLA for somatrogon to treat pediatric patients with growth hormone deficiency. The revie…

Leave a comment

Your email address will not be published. Required fields are marked *